Unlocking the Power of ADCs: ASCO Highlights and Beyond with Targeted Pulse

The Power of ADCs in Oncology Treatment

Introduction

The 2024 ASCO Annual Meeting presented intriguing data on the benefits of ADCs in advanced cancer treatments. In this 3-part series, Targeted OncologyTM explores various data demonstrating the improving oncolytic field across cancer types through the use of ADCs. In this third installment, we cover various ADCs, including belantamab mafodotin (Blenrep), datopotamab deruxtecan (Dato-DXd; DS-1062a), and more.

The Exciting Field of ADCs in Breast Cancer Treatment

The field of ADCs in breast cancer treatment is exciting as promising results have been reported with ADCs. The recent developments with Dato-DXd are particularly promising. If Dato-DXd gains approval, it could lead to a lot of discussion about sequencing of therapies, as there will be patients who are candidates for multiple ADCs. Tanya Gupta, MD of Stanford University Department of Medicine, Division of Medical Oncology, expresses her enthusiasm regarding the area of ADCs in breast cancer treatment.

Improvement in First-line Treatment of Advanced RCC with Nivolumab-cabozantinib

There are multiple immunotherapy-based combination treatments with similar efficacies approved for first-line treatment of advanced RCC. Therefore, it’s important to characterize patient survival time after treatment initiation. Over the 4-year period since first-line protocol therapy initiation, nivolumab plus cabozantinib achieved a 1.5-times longer mean TFS vs sunitinib, according to Charlene Mantia, MD, a medical oncologist at Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School in Boston, Massachusetts.

Robust, Durable Antitumor Activity with Envafolimab-lenvatinib in Endometrial Cancer Treatment

The combination of envafolimab plus lenvatinib has shown robust durable antitumor activity and demonstrates a manageable safety profile. This combination serves as an effective treatment option for those with previously treated advanced non-MSI-H/non-dMMR endometrial cancer—a population with a high unmet need, according to investigators.

JNJ-69086420: A Promising Therapy for Metastatic CRPC Treatment

JNJ-69086420 is an alpha emitting radioligand therapy that is the first to target hK2 and elicits deep and durable biochemical responses in metastatic CRPC patients. Although the therapy is promising, interstitial lung disease and thrombocytopenia were noted as a dose-limiting factor. These factors can be mitigated using the adaptive dosing schedule and dose cap, as noted by Michael J. Morris, MD, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center.

Enfortumab Vedotin Plus Pembrolizumab Improves Treatment for Urothelial Cancer

Patients with locally advanced and metastatic urothelial cancer have a poor prognosis with a low 5-year survival rate. Enfortumab vedotin plus pembrolizumab treatment has shown promise with significant impacts on patient’s quality of life, functioning, and disease symptoms. Shilpa Gupta, MD, notes this development during the presentation at the 2024 American Society for Clinical Oncology Annual Meeting.

New Treatment Regimens Approved for Various Cancer Types

The FDA has approved various treatment regimens for different cancer types such as atezolizumab for non–small cell lung cancer and ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma. Additionally, the FDA has greenlighted blinatumomab for the treatment of patients with CD19-positive, B-cell precursor acute lymphoblastic leukemia following a priority review designation. These recent developments could lead to promising treatments and improved outcomes for patients diagnosed with different forms of cancer.

Valuable Insights into a Patient Group with Limited Prior Data

MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This could lead to valuable insights for a patient group with limited prior data and aid in developing tailored interventions for improved treatments.

The Role of Technology in Community Oncology

Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology. As technology continues to advance, it could lead to improved processes and better outcomes for patients.

Conclusion

The developments with ADCs and recent approvals of new treatment regimens for various cancer types provide promising treatments and improved outcomes for patients. Continued research and trials could lead to further advancements in the oncolytic field and ultimately, improve patient outcomes.

Originally Post From https://www.targetedonc.com/view/the-targeted-pulse-an-in-depth-overview-on-the-power-of-adcs-highlights-from-asco-and-more